Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07169942 · ClinicalTrials.gov registry record · Phase 2
Aleniglipron Phase 2 Body Composition Study
A Phase 2 study of Obesity, Overweight, or Chronic Weight Management, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
- 11
- Study locations
NCT07169942: Active Phase 2 study of Obesity, Overweight, or Chronic Weight Management, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
NCT07169942 is a Phase 2 study of Obesity, Overweight, or Chronic Weight Management that is active but no longer recruiting, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 71 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07169942, a Phase 2 study of Obesity, Overweight, or Chronic Weight Management, is active but no longer recruiting, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.
Conditions Studied
Interventions
- DRUG aleniglipron or placebo
Study Locations (11)
South Carolina
- Research Site - Moncks Corner
- Research Site - North Charleston
Texas
- Research Site - Austin
- Research Site - San Antonio
Arizona
- Research Site - Phoenix
Illinois
- Research Site - Chicago
Minnesota
- Research Site - Richfield
Missouri
- Research Site - City of Saint Peters
New York
- Research Site - Rochester
North Carolina
- Research Site - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2025-08-15 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT07169942 still lists
NCT07169942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Obesity, Overweight, or Chronic Weight Management appearing as the primary indexed condition, and to 1 intervention - of which aleniglipron or placebo is the first listed.
NCT07169942 lists 11 locations in 9 states (South Carolina, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT07169942 about?
NCT07169942 is a clinical study titled "Aleniglipron Phase 2 Body Composition Study". This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of alenigli...
What is the current status of trial NCT07169942?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2025-08-15. Estimated completion is 2026-10.
What conditions does trial NCT07169942 study?
This clinical trial studies the following conditions: Obesity, Overweight, or Chronic Weight Management.
What interventions are being tested in trial NCT07169942?
The interventions under investigation include: aleniglipron or placebo (DRUG).
Who is sponsoring clinical trial NCT07169942?
This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07169942 being conducted?
This trial has 11 study locations across Arizona, Illinois, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity, Overweight, or Chronic Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07169942's enrollment target sits among peer trials
71 936th of 2000 higher than 1,064 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI